FDG PET/CT before and after selective internal radiation therapy (SIRT) can help predict survival among patients with breast cancer with hepatic metastases, researchers found.
FDG PET/CT before and after selective internal radiation therapy (SIRT) can help predict survival among patients with breast cancer with hepatic metastases, researchers found.
A study published in the March issue of the Journal of Nuclear Medicine involved 58 women with breast cancer who underwent SIRT a mean of 467 weeks +/- 365 weeks following initial diagnosis. The patients underwent both a whole-body FDG PET/CT 3D scan and contrast-enhanced MRI of the liver before beginning treatment. These were repeated three months following treatment in 43 of the patients.
The researchers measured the maximum standardized uptake value (SUVMAX) of the hepatic metastases and compared the findings from the second exam to the first. They used up to five of the most notable hepatic metastases.
Researchers found that patients who responded favorably to the treatment, having a greater chance of survival, had a decrease of greater than 30 percent from baseline; those who had new metastases or a decrease of less than 30 percent meant poor or no response, and did not predict survival. “Furthermore, a high pretherapeutic SUVMAX (higher than 20) was associated with a significantly shorter median survival than was an SUVMAX of equal to or lower than 20,” wrote the authors.
Overall median survival after SIRT was 47 weeks, 65 weeks for favorable responders and 43 weeks for non-responders. Of the 43 patients who were tested after treatment, 11 (26 percent) had partial response to treatment, 27 (63 percent) had stable disease, and five (11 percent) had progressive disease.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.